

Pandemic Proposal Weekly Monitor Based on the IMF Staff Discussion Note


2 September 2022*

*Based on the IMF SDN "A Proposal to End the COVID-19 Pandemic"

Financing Gaps & Progress on Dose Sharing

Funding Needs by Pillar and Major Outcome Category

(in USD billion)



Source and Notes: ACT-A Strategic Plan and Budget. The procurement numbers for the vaccine pillar is based on a common framework to assess and quantify risk factors between COVAX/GMA, the ACT-A Hub, and IMF. Starting in early November 2021, this assessment will be regularly updated and shared to ensure a forward-looking accounting of downside risks and progress towards addressing those risks, and to enhance transparency of the nature and size of the risks. Last Update: 28 Oct 2021

Dose Donations Pledges and shipped (in millions)

% Delivered **Dose Donations Delivered To Date Doses Announced** Verified By Pledge at Cardbis of G7 Summit or of Total Confirmed Country As Bay G7 Summit or Jun'21 Pledge **Through Direct** Through Direct Supply by Through Through Announced Total 2021-2022 COVAX COVAX COVAX** **Donations Total Donations** Of Jun'21 to COVAX Delivered **Doses Delivered** Country 35 -35 60 19 41 0 58% Australia 15.1 51 15 29% Canada 51 1 14 1 12/8/21 116% 13 23 19 21 60 37 40 11.3 134% 67% Japan 30 26.2 107 100 36 30 11/8/21 36% 34% United Kingdom 100 228 53% **United States** 900 819 81 308 80 693.4 580 34% 377 257% 595 491 293.6 63% **European Union** 84 311 66 147 122% 6 •o/w France 145 138 7 73 67 64.1 11/25/21 51% 60 175 96 99.1 358% •o/w Germany 164 11 107 11 61% 30 •o/w Italy 72 66 6 51 45 6 43.9 337% 70% 15 •o/w Spain 74 64 10 48 45 3 46.3 11/22/21 65% •o/w Portugal 3 3 2.4 7 7 11/19/21 92% •o/w Belgium 15 0 9 9 0 8.2 61% 1.4 •o/w Finland 4 3 3 -69% 5.9 •o/w Sweden 11 8 12/2/21 69% 4.7 7 •o/w Denmark 11 11 100% 21 32 22 9 15 •o/w Netherlands 16.3 11/24/21 68% 0 2 0 •o/w Ireland 4 1.3 47% 34 45 37 12 26 •o/w Others 82% Hong Kong SAR, China 11.5 12% **New Zealand** 9 3 3 3 0 0.9 31% 97% 6 Norway 2 -3 2 South Korea 40% 2 -22% **Switzerland** 8 1.6 Turkey 5 5 4 -4 0 76% UAE 3 -4 3 85% 14 -India 14 14 14 100% 191 146 -146 China 191 76% 42 21 Other 28 0 20 49%

1,549

2,066

Total

483

1,012

614

399

1054


870

61%

49%

Only 43% of COVAX-contracted doses and 37% of AVAT-contracted have been supplied for delivery so far

COVID-19 Vaccine Supply Tracker: Deliveries to COVAX & AVAT (Mn doses)




Sources and Notes: COVAX, UNICEF, Africa CDC, IMF staff calculations. Committed doses are doses that the COVAX facility is required to procure. Support from e US has allowed COVAX to secure 1b Pfizer doses. These include a donation of 700m doses, and the rest 300m doses is treated as non-donations. However, for this presentation all 1b facilitated doses are included in the Pfizer category. The secured supply agreement numbers for SII-AstraZeneca and SII-Novavax are approximated based on COVAX Facility candidate-specific supply information. The dose donations are based on COVAX estimates based on commitments from donors to share doses bilaterally with the COVAX facility.

Country Level Tracking of Key SDN Targets

Where are COVID-19 Cases Surging Now?

Ratio of Current Cases to 2020 Peak




Note: 2020 Peak is Defined as 95% percentile highest daily cases observed in 2020. Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 2 Sep 2022

Secured Vaccine Doses and/or Expected Vaccine Supply

Target ≥ 140% of Population

Secured Vaccines and/or Expected Vaccine Supply (doses, % of Total Population)




Note: This includes coverage from bilateral contracts, regional deals, COVAX, in-kind donation, domestic production, and contracts supported by MDB financing.

Some contracts are unobserved, which may lead to under-reporting of coverage in some countries. Optional contracts, and unallocated AVAT doses are excluded to remain conservative.

Country borders or names do not necessarily reflect the IMF's official position. Source: IMF-WHO COVID-19 Vaccine Supply Tracker. Last Update: 2 Sep 2022


Share Who Received At Least One COVID-19 Vaccine Dose

Share of People Who Received At Least One Vaccine Dose (% of population)



Vaccine Delivery (1): Daily Speed Observed So Far (Maximum)


Maximum Observed Daily Vaccination Rate (per 100 people)



Note: Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 2 Sep 2022

Vaccine Delivery (2): Daily Speed Observed So Far (Average)

Average Observed Daily Vaccination Rate (per 100 people)




Note: Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 2 Sep 2022

Diagnostics

Target = Daily Tests > 1 per 1000 people


Average Daily Tests (per 1000 people)



Genomic Surveillance: Percent of COVID Cases Sequenced

Target > 5% of Cases

Genomic Surveillance: Percent of COVID Cases Sequenced




Note: Country borders or names do not necessarily reflect the IMF's official position. Source: GISAID. Last Update: 2 Sep 2022

NGS Capacity for SARS-CoV-2 Genomic Surveillance in LMICs


Assessed with a 4-tier country-level classification framework

NGS Capacity for SARS-CoV-2 Genomic Surveillance



Variant VOC Delta: Percent of Delta in past 4 weeks

Variant Genome: Percent of Delta Variant



Country-Level Dashboard

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Afghanistan |
|---|----------------|-------|-------|-------|-------|--------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 132.8 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 12.8 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 24.37 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 59.08 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .22 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 18.52 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 17.14 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .05 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 113 |
| Date approved | | | | | | Mar 18, 2021 |
| Date effective | | | | | | Apr 15, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | 50 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.3 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.2 |
| Therapeutics – Others (USD mn.) | | | | | | 2.4 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁶ |
| Date of Publication | | | | | | Jun, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Albania |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 119.67 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 88.79 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 18.83 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 12.05 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 44.1 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .37 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 42.63 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .02 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 17 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Algeria |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 115.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 34.85 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .45 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 15.51 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 44.89 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 26.68 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .1 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .8 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 18 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Angola |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 168.46 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 64.83 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 4.63 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 19 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 23.53 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 56.94 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .1 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 45.24 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .04 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 3.3 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.25 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 150 |
| Date approved | | | | | | Jul 29, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.2 |
| RDT diagnostic tests (USD mn.) | | | | | | .6 |
| PPE (USD mn.) | | | | | | 5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 6.1 |
| Therapeutics – Others (USD mn.) | | | | | | 3.2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 19 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Antigua and Barbuda |
|---|----------------|-------|-------|-------|-------|----------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 273.32 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 17.72 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 154.31 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 60.77 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 40.52 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 66.54 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 50.34 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .05 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .36 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.66 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 20 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Argentina |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 332.91 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 265.02 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 8.55 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 15.49 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 43.85 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 83.37 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 72.29 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .19 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 28.7 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .21 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 500 |
| Date approved | | | | | | Sep 30, 2021 |
| Date effective | | | | | | Oct 6, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 21 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Armenia |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 125.05 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 60.64 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 50.18 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 14.23 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 35.32 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 72.17 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .53 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .3 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .04 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .7 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | .4 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .5 |
| Therapeutics – Others (USD mn.) | | | | | | 2.6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 2 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Aruba |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | • |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 78.33 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 8.2 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 23 |
| Date of Publication | | | | | | |

| 7.40-01-01-10 | | | | <u>, </u> | | <u>'</u> |
|---|---------|-------|-------|--|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Australia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 990.04 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 988.05 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 1.99 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 83.96 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 83.16 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.77 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 41.68 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.43 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 24 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Austria |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 76.44 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 48.24 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .07 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 7.11 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 8.09 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.31 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 25 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Azerbaijan |
|---|---------|-------|-------|-------|-------|------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 149.1 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 127.85 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.47 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 19.78 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 47.15 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .32 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.7 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .02 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.6 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .1 |
| Therapeutics – Others (USD mn.) | | | | | | .6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 26 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bahamas, The |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 169.87 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 113.9 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 45.89 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 10.08 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 40.01 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.73 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .19 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 34.86 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 27 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bahrain |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 260.66 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 248.77 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 5.72 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 6.17 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 83.74 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.92 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.93 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 27.71 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.18 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 28 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bangladesh |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | - Dangia de Sin |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 269.11 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 64.94 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 19.4 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 121.8 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 62.98 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 71.58 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 80.05 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 27.02 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 27.61 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .36 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 500 |
| Date approved | | | | | | Mar 18, 2021 |
| Date effective | | | | | | Apr 15, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | 940 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .6 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 10.1 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 29 |
| Date of Publication | | | | | | May, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Barbados |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 183.94 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 16.32 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 127.7 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 39.92 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 54.91 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 61.41 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | 1.89 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 18.12 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .18 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 30 |
| Date of Publication | | | | | | |

| 2010.00 | | | | * | | |
|---|---------|-------|-------|-------|-------|----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Belarus |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 173.77 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 141.89 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 31.88 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 67.93 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .47 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .82 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .05 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 31 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Belgium |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 78.87 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 96.44 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .66 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 26 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.28 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 32 |
| Date of Publication | | | | | | • |

| 50.120 | | | | * | | <u>'</u> |
|---|---------|-------|-------|-------|-------|-----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Belize |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 266.96 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 184.72 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 45.15 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 37.09 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 54.83 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 53.05 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.53 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 14.51 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.4 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 3 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bermuda |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 74.25 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 11.16 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 8.72 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.2 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 35 |
| Date of Publication | | | | | | |

| bnutan | | | | y nate and denomic 3 | | idicative. Last updated on 2 sep |
|---|---------|-------|-------|----------------------|-------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bhutan |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 325.89 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 25.5 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 164.44 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 135.94 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 86.7 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 80.69 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .05 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 32.44 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 12.25 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.3 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | 36 |
| Date of Publication | | | | | | Oct, 2018 |

| 5011714 | | | | , | 9 | | |
|---|---------|-------|-------|-------|-------|-----------|----|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bolivia | |
| Vaccines | | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 253.69 | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 98.88 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 39.3 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 115.51 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 50.64 | |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 59.33 | |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 | |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 38.26 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track | |
| Diagnostics | | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .37 | |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 7.26 | |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .03 | |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | | |
| AVAT orders placed | | | | | | • | |
| World Bank financing for vaccines (USD mn.) | | | | | | • | |
| Date approved | | | | | | | |
| Date effective | | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • | |
| Global Fund COVID-19 Response Mechanism | | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .9 | |
| RDT diagnostic tests (USD mn.) | | | | | | 1.3 | |
| PPE (USD mn.) | | | | | | 0 | |
| Therapeutics – Oxygen (USD mn.) | | | | | | .8 | |
| Therapeutics – Others (USD mn.) | | | | | | 0 | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | | |
| Risk of External Debt Distress | | | | | | | |
| Risk of Overall Debt Distress | | | | | | | 37 |
| Date of Publication | | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bosnia and Herzegovina |
|---|---------|-------|-------|-------|-------|-------------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 124.23 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 27.58 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 86.46 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 10.19 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 25.87 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 66.69 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .13 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .14 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .38 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 38 |
| Date of Publication | | | | | | |

| | | | | , | | <u> </u> |
|---|----------------|-------|-------|-------|-------|-----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Botswana |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 240.87 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 37.54 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 95.13 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 60.12 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 48.08 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 58.44 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 91.19 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .28 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.37 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Brazil |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 283.46 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 212.29 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 2.44 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 7.89 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 60.84 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 80.12 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 77.56 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .08 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .23 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .51 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 40 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Brunei Darussalam |
|---|---------|-------|--------|--------|-------|-------------------|
| | largets | LIC | LIVIIC | Olviic | THE | Brunei Darussalam |
| Vaccines Convert Vaccines (Dance (Vaf Barrulation) | . 440 | 42C F | 202.0 | 225.4 | F44.6 | 212.05 |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 313.85 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 211.29 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 79.72 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 22.83 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 99.65 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .22 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 6.89 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.33 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 41 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Bulgaria |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 30.05 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 34.72 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .68 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 7.77 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.47 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | • 42 |
| Date of Publication | | | | | | |

| Darkina raso | | | | <i>'</i> | | <u>'</u> |
|---|---------|-------|-------|----------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Burkina Faso |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 124.65 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 4.65 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 7.64 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 38.7 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 20.08 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.15 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 43 |
| Date of Publication | | | | | | Nov, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Burundi | |
|---|----------------|-------|-------|-------|-------|-----------|----|
| Vaccines | | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 124.08 | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 4.08 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | .14 | |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 5.01 | |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 | |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track | |
| Diagnostics | | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .14 | |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 2.36 | |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .32 | |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | | |
| AVAT orders placed | | | | | | No | |
| World Bank financing for vaccines (USD mn.) | | | | | | • | |
| Date approved | | | | | | | |
| Date effective | | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • | |
| Global Fund COVID-19 Response Mechanism | | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 4.9 | |
| RDT diagnostic tests (USD mn.) | | | | | | 5.3 | |
| PPE (USD mn.) | | | | | | 7 | |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.5 | |
| Therapeutics – Others (USD mn.) | | | | | | .9 | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | | |
| Risk of External Debt Distress | | | | | | High | |
| Risk of Overall Debt Distress | | | | | | ••• | 44 |
| Date of Publication | | | | | | Mar, 2015 | |

| Cabo Verde | | INO | tes. The Test Positivit | y rate and denomic 3 | urveillance targets are indicat | ive. Last updated on 2 se |
|---|----------------|-------|-------------------------|----------------------|---------------------------------|---------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cabo Verde |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 210.69 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 103.96 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 106.73 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 52.4 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 80.25 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .2 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 32.2 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .76 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .94 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | 10 | 5 |
| Date approved | | | | | Jun 29, 2021 | Feb 11, 2021 |
| Date effective | | | | | Jul 23, 2021 | Feb 16, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .3 |
| Therapeutics – Others (USD mn.) | | | | | | .3 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High 45 |
| Date of Publication | | | | | | Oct, 2020 |

| Cambodia | | INO | tes. The lest rositivit | y Nate and Genomic 3 | ui veillance targets are i | ndicative. Last updated on 2 Sep |
|---|----------------|-------|-------------------------|----------------------|----------------------------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cambodia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 444.48 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 133.42 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 231.06 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 87.33 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 88.78 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 14.7 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.53 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 3.5 |
| Date approved | | | | | | Jun 25, 2021 |
| Date effective | | | | | | Jul 30, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 8.2 |
| RDT diagnostic tests (USD mn.) | | | | | | .4 |
| PPE (USD mn.) | | | | | | 4.1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 6.2 |
| Therapeutics – Others (USD mn.) | | | | | | 1.1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 46 |
| Date of Publication | | | | | | Dec, 2019 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cameroon |
|---|----------------|-------|-------|-------|-------|--------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 120.33 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .73 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 19.59 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 4.51 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 15.2 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 3.98 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.32 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.07 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ⁴⁷ |
| Date of Publication | | | | | | Jul, 2021 |

| | | | | | _ | |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Canada |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 832.39 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 827.21 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 2.63 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 2.55 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 82.7 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 84.84 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .09 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .62 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 8.73 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 10.14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 4 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cayman Islands |
|---|----------------|-------|-------|-------|-------|-----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | • |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 88.2 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 5.55 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 34 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 49 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Central African Republic |
|---|---------|-------|-------|-------|-------|---------------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 123.05 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 3.05 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 22.84 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 54.33 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 35.44 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .74 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ⁵⁰ |
| Date of Publication | | | | | | Jan, 2021 |

| Chad | | 140 | tes. The reservositivit | y nate and denomic 5 | | ilulcative. Last upuateu oi | 11 Z 3CP Z |
|---|----------------|-------|-------------------------|----------------------|-------|-----------------------------|------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Chad | |
| Vaccines | | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 121.18 | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.18 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 21.01 | |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 45.7 | |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .16 | |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 13.38 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track | |
| Diagnostics | | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 0 | |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .44 | |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .65 | |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | | |
| AVAT orders placed | | | | | | No | |
| World Bank financing for vaccines (USD mn.) | | | | | | 20 | |
| Date approved | | | | | | Sep 30, 2021 | |
| Date effective | | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • | |
| Global Fund COVID-19 Response Mechanism | | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.4 | |
| RDT diagnostic tests (USD mn.) | | | | | | .2 | |
| PPE (USD mn.) | | | | | | .3 | |
| Therapeutics – Oxygen (USD mn.) | | | | | | 3 | |
| Therapeutics – Others (USD mn.) | | | | | | 0 | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | | |
| Risk of External Debt Distress | | | | | | High | |
| Risk of Overall Debt Distress | | | | | | High | 51 |
| Date of Publication | | | | | | Jul, 2020 | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Chile |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 451.84 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 439.83 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 12.01 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 90.6 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 92.78 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .13 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.76 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 15.02 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .75 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 52 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | China |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 264.82 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 71.74 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .35 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 192.73 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 88.95 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .5 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .04 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 53 |
| Date of Publication | | | | | | |

| | | | | * | | ' |
|---|---------|-------|-------|-------|-------|----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Colombia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 273.72 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 181.95 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 33 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 58.78 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 70.81 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.4 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .17 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 8.5 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .36 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .9 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 54 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Comoros |
|---|----------------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 201.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 22.51 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 78.79 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 46.5 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 58.85 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .4 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 0 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .2 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .4 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 21 |
| Date approved | | | | | | Jun 29, 2021 |
| Date effective | | | | | | Jul 15, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 55 |
| Date of Publication | | | | | | Apr, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Congo, Dem Rep |
|---|----------------|-------|-------|-------|-------|----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 151.43 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | .01 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 2.65 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 28.77 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 2.7 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 29.71 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 4.82 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 9.68 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.32 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 200 |
| Date approved | | | | | | Jun 29, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 9.6 |
| RDT diagnostic tests (USD mn.) | | | | | | 2.8 |
| PPE (USD mn.) | | | | | | 8.7 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 56 |
| Date of Publication | | | | | | Jul, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Congo, Rep |
|---|---------|-------|-------|-------|-------|----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 145.51 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 21.94 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 7.07 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 16.51 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 11.21 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 25.75 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 27.74 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.48 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 12 |
| Date approved | | | | | | Jun 2, 2021 |
| Date effective | | | | | | Aug 27, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.1 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | 2.2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1 |
| Therapeutics – Others (USD mn.) | | | | | | .8 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 57 |
| Date of Publication | | | | | | Jan, 2020 |

| COSTA TITCA | | | | * | | ' |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Costa Rica |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 295.76 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 204.33 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 41.62 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 49.81 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 81.33 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 80.24 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .16 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.32 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 17.6 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .61 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 58 |
| Date of Publication | | | | | | |

| 000 0 110110 | | | | , | | <u> </u> |
|---|---------|-------|-------|-------|-------|---------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cote d'Ivoire |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 121.6 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 4.07 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.39 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 36.15 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 31.55 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 76.35 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .16 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 32.12 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 3.1 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .87 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 100 |
| Date approved | | | | | | Apr 16, 2021 |
| Date effective | | | | | | May 27, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 59 |
| Date of Publication | | | | | | Jul, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Croatia |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 55.36 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 59.71 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .71 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 21.67 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.03 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 60 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cuba |
|---|----------------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 401.73 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 261.73 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 140 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 88.72 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 91.02 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .42 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .17 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 63 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Cyprus |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 648.43 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 16.12 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 72.05 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 63.05 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 68.13 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .24 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 62 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Czech Republic |
|---|----------------|-------|-------|-------|-------|-----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 634.04 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.74 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 65.52 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.79 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .05 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .6 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.1 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.2 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 6 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Denmark |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 81.71 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 100 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | 1.11 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 19.4 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 17.1 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | • 64 |
| Date of Publication | | | | | | |

| | | | | <u>'</u> | | <u>'</u> |
|---|---------|-------|-------|----------|-------|-----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Djibouti |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 219.69 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 9.98 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 129.72 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 18.26 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 13.02 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 31.48 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .37 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 4.56 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .7 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | .2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .4 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High 65 |
| Date of Publication | | | | | | May, 2020 |

| | | | | 1 | | <u> </u> |
|---|---------|-------|-------|-------|-------|-----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Dominica |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 397.37 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 217.95 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 179.42 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 42.21 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 30.09 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 70.6 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 3.36 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .26 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | 66 |
| Date of Publication | | | | | | Jun, 2018 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Dominican Republic |
|---|---------|-------|-------|-------|-------|--------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 286.85 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 281.9 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .73 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.23 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 54.27 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.93 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .1 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 15.24 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .24 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 1 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .1 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 67 |
| Date of Publication | | | | | | |

| 20000 | | | | <u>, </u> | | <u> </u> |
|---|---------|-------|-------|--|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Ecuador |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 303.69 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 147.75 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 37.84 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 34.01 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 84.09 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 79.16 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 68.94 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .61 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 27.1 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .71 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 150 |
| Date approved | | | | | | Apr 1, 2021 |
| Date effective | | | | | | May 20, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | .6 |
| PPE (USD mn.) | | | | | | .6 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .5 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 68 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Egypt, Arab Rep |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 223.84 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 91.12 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 7.96 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 44.76 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 35.81 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 41.64 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .76 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .51 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.9 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 69 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | El Salvador |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 253.21 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 144.82 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 28.39 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 68.59 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 83.58 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 27.66 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .74 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 10.6 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .26 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 50 |
| Date approved | | | | | | Apr 16, 2021 |
| Date effective | | | | | | Sep 23, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 1.5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .1 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 70 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Equatorial Guinea |
|---|---------|-------|-------|-------|-------|--------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 59.31 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 34.49 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 20.69 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.14 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 13.09 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 56.82 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .2 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.57 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.26 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 71 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Eritrea |
|---|---------|-------|-------|-------|-------|---------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 120 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | • |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | • |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | • |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 72 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Estonia |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 63.62 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 72.71 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .96 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.83 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.21 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 73 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Eswatini |
|---|----------------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 124.35 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 44.35 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 28.69 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 92.02 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 32.74 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .06 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 4.34 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.44 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 8 |
| Date approved | | | | | | Apr 16, 2021 |
| Date effective | | | | | | Oct 11, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .8 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | 1.9 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.8 |
| Therapeutics – Others (USD mn.) | | | | | | .3 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | • 74 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Ethiopia | |
|---|---------|-------|-------|-------|-------|-----------|----|
| Vaccines | | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 114.34 | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 11.79 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 2.55 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 30.52 | |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 78.61 | |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 | |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 20.3 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track | |
| Diagnostics | | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 | |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 13.25 | |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .13 | |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | | |
| AVAT orders placed | | | | | | Yes | |
| World Bank financing for vaccines (USD mn.) | | | | | | • | |
| Date approved | | | | | | | |
| Date effective | | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • | |
| Global Fund COVID-19 Response Mechanism | | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 10 | |
| RDT diagnostic tests (USD mn.) | | | | | | 20.3 | |
| PPE (USD mn.) | | | | | | 30.4 | |
| Therapeutics – Oxygen (USD mn.) | | | | | | 26.5 | |
| Therapeutics – Others (USD mn.) | | | | | | 5.9 | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | | |
| Risk of External Debt Distress | | | | | | High | |
| Risk of Overall Debt Distress | | | | | | High | 75 |
| Date of Publication | | | | | | Apr, 2020 | |

| | | | | • | | · |
|---|---------|-------|-------|-------|-------|---------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Faroe Islands |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 77.32 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | • |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .05 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | • |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 13.59 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .12 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 76 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Fiji |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 268.28 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 188.28 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 68.98 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 86.05 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .08 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 27.74 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.61 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .78 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 77 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Finland |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 78.41 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 82.19 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .21 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .82 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 33.1 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.96 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 78 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | France |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 78.66 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 71.81 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 3.66 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 22.7 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.53 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 79 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Gabon |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 107.72 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 31.6 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 34.64 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 41.48 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 10.98 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 34.95 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .09 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 3.89 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .3 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .1 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 80 |
| Date of Publication | | | | | | |

| COVID 10 Health Tools | Targets | | | • | | Casalia The |
|---|---------|-------|-------|-------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Gambia, The |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 135.57 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 4.85 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 10.72 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 13.54 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 91.23 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 18.4 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 11.07 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 8 |
| Date approved | | | | | | Apr 16, 2021 |
| Date effective | | | | | | May 6, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 2.6 |
| PPE (USD mn.) | | | | | | 3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .8 |
| Therapeutics – Others (USD mn.) | | | | | | .5 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High 81 |
| Date of Publication | | | | | | Jan, 2022 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Georgia |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 142.25 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 103.02 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 35.2 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.02 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 33.96 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 81.22 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 3.28 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .12 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | 15 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .8 |
| RDT diagnostic tests (USD mn.) | | | | | | 2.2 |
| PPE (USD mn.) | | | | | | .6 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .4 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | |
| Date of Publication | | | | | | |

| cermany | | | | <u>* </u> | | · |
|---|---------|-------|-------|--|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Germany |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 668.06 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 668.06 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 76.05 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 81.93 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.07 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 41.8 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.38 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 8 |
| Date of Publication | | | | | | |

| Gnana | | 140 | tes. The reserrositivit | .y Nate and denomic 5 | ar vemarice targets are r | ildicative. Last updated oil 2 sep |
|---|----------------|-------|-------------------------|-----------------------|---------------------------|------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Ghana |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 145.02 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | .95 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 10.75 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 53.32 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 24.69 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 57.38 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 32.16 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 0 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 26.32 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.31 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 200 |
| Date approved | | | | | | Jun 10, 2021 |
| Date effective | | | | | | Jul 15, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .3 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | 2.3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 10.9 |
| Therapeutics – Others (USD mn.) | | | | | | 1.3 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ⁸⁴ |
| Date of Publication | | | | | | Jul, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Gibraltar |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 126.79 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .19 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | • |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 16.41 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 14.14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 85 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Greece |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 73.1 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 75 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 7.65 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 8.27 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .42 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 8 |
| Date of Publication | | | | | | |

| | | | | * | | · · · |
|---|---------|-------|-------|-------|-------|----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Grenada |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 202.36 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 17.65 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 70.12 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 114.6 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 31.11 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 39.31 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 55.18 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.12 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.72 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .3 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 87 |
| Date of Publication | | | | | | Apr, 2020 |

| Guatemala | | No | Notes: The Test Positivity Rate and Genomic Surveillance targets are indicative. Last updated of | | | | | |
|---|---------|-------|--|-------|-------|-----------|--|--|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Guatemala | | |
| Vaccines | | | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 128.2 | | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 43.84 | | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 50.19 | | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 34.18 | | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 | | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 38.59 | | |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 88.97 | | |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .15 | | |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • | | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track | | |
| Diagnostics | | | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .51 | | |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • | | |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .22 | | |
| inancing for Vaccines, Diagnostics, Treatments, PPE | | | | | | | | |
| AVAT orders placed | | | | | | • | | |
| World Bank financing for vaccines (USD mn.) | | | | | | • | | |
| Date approved | | | | | | • | | |
| Date effective | | | | | | • | | |
| ADB financing for vaccines (USD mn.) | | | | | | • | | |
| Global Fund COVID-19 Response Mechanism | | | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 | | |
| RDT diagnostic tests (USD mn.) | | | | | | 0 | | |
| PPE (USD mn.) | | | | | | 0 | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 | | |
| Therapeutics – Others (USD mn.) | | | | | | 0 | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | | | |
| Risk of External Debt Distress | | | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 88 | | |
| Date of Publication | | | | | | • | | |

| Guinea | | INO | tes. The lest rositivit | y Nate and Genomic 3 | urveillance targets are i | ndicative. Last updated on 2 Sep |
|---|----------------|-------|-------------------------|----------------------|---------------------------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Guinea |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 149.53 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 17.04 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 3.1 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 29.39 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 19.16 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 68.57 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .09 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 33.5 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.12 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 28.2 |
| Date approved | | | | | | Jun 29, 2021 |
| Date effective | | | | | | Aug 17, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 89 |
| Date of Publication | | | | | | Jun, 2021 |

| Guinea-Bissau | | | | , | | indicative. Last updated on 2 Sep |
|---|---------|-------|-------|-------|-------|-----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Guinea-Bissau |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 162.22 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 26.1 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 16.13 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 17.53 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 41.04 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 26.44 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .07 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 2.47 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .56 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 5 |
| Date approved | | | | | | Jun 29, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .7 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | 3.2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .9 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High 90 |
| Date of Publication | | | | | | Jan, 2023 |

| Guyana | | | tes. The lest rositivit | y nate and denomic 5 | | ndicative. Last updated on 2 sep |
|---|---------|-------|-------------------------|----------------------|-------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Guyana |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 252.1 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 113.88 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 54.11 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 4.11 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 57.37 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 79.52 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 23.3 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .2 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 5 |
| Date approved | | | | | | Jun 29, 2021 |
| Date effective | | | | | | Sep 30, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .4 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.1 |
| Therapeutics – Others (USD mn.) | | | | | | .2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 91 |
| Date of Publication | | | | | | Aug, 2019 |

| Haiti | | 110 | tes. The lest rositivit | y Nate and Genomic 3 | di velliance targets are in | idicative. Last updated on 2 Sep |
|---|----------------|-------|-------------------------|----------------------|-----------------------------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Haiti |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 100 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 1.46 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 34.61 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 5.84 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 3.63 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High 92 |
| Date of Publication | | | | | | Apr, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Honduras |
|---|---------|-------|-------|-------|-------|---------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 215.46 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 126.2 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 5.84 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 83.42 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 54.07 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 86.01 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .2 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 25.86 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .12 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .05 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 20 |
| Date approved | | | | | | Apr 16, 2021 |
| Date effective | | | | | | Sep 30, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 93 |
| Date of Publication | | | | | | Sep, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Hong Kong SAR, China |
|---|----------------|-------|-------|-------|-------|----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 282.72 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 282.72 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 87.76 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 87.68 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .27 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | • |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 18.48 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .38 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | • |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 94 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Hungary |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 704.96 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 704.96 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 63.88 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 50.23 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .45 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .03 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 95 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Iceland |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 363.46 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 363.46 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 78.36 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 64.54 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .83 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 5.38 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 96 |
| Date of Publication | | | | | | • |

| - Tala | | | | , | | | |
|---|---------|-------|-------|-------|-------|----------|----|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | India | |
| Vaccines | | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 200.78 | |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 179.13 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .12 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 21.53 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 66.96 | |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.97 | |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .19 | |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track | |
| Diagnostics | | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .22 | |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 2.78 | |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .51 | |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | | |
| AVAT orders placed | | | | | | • | |
| World Bank financing for vaccines (USD mn.) | | | | | | • | |
| Date approved | | | | | | | |
| Date effective | | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • | |
| Global Fund COVID-19 Response Mechanism | | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 | |
| RDT diagnostic tests (USD mn.) | | | | | | 0 | |
| PPE (USD mn.) | | | | | | 0 | |
| Therapeutics – Oxygen (USD mn.) | | | | | | 75 | |
| Therapeutics – Others (USD mn.) | | | | | | 0 | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | | |
| Risk of External Debt Distress | | | | | | | |
| Risk of Overall Debt Distress | | | | | | | 97 |
| Date of Publication | | | | | | | |

| | | | | 1 | | <u> </u> |
|---|---------|-------|-------|-------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Indonesia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 216.6 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 128.71 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 7.89 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 62.3 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .08 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 30.12 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .3 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .52 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 509.9 |
| Date approved | | | | | | Jun 17, 2021 |
| Date effective | | | | | | Aug 19, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 6.8 |
| Therapeutics – Others (USD mn.) | | | | | | 2.7 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 98 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Iran, Islamic Rep |
|---|----------------|-------|-------|-------|-------|-------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 223.54 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 188.04 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 14.32 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 21.18 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 66.03 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .14 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .78 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .03 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .2 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | .2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | |
| Date of Publication | | | | | | • |

| | | | | - | | · |
|---|---------|-------|-------|-------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Iraq |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 93.93 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 41.28 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.82 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 24.84 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 25.98 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 17.89 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 89.88 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .13 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .92 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .05 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 100 |
| Date approved | | | | | | Sep 24, 2021 |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 100 |
| Date of Publication | | | | | | • |

| | | | | , | | <u>'</u> |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Ireland |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 81.21 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 67.47 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .58 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 32 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 5.32 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 101 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Isle of Man |
|---|---------|-------|-------|-------|-------|-------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | • |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | • |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | • |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | • |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 79.64 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | • |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | • |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 102 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Israel |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 554.05 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 554.05 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 66.22 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 41.82 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 33.3 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.8 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 103 |
| Date of Publication | | | | | | |

| italy | | | | • | | · |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Italy |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 748.26 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 748.26 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 80.96 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 98.6 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.45 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 20.53 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .67 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 104 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Jamaica |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 186.1 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 3.36 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 54.1 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 62.31 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 66.33 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 25.7 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 39.16 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .22 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 21.64 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.59 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 105 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Japan |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 667.98 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 667.98 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 82.43 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 100 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .4 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.37 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 14.83 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.97 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 106 |
| Date of Publication | | | | | | |

| | | | | | | · |
|---|---------|-------|-------|-------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Jordan |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 128.33 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 111.99 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 11.69 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.65 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 40.89 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .36 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .09 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 63.75 |
| Date approved | | | | | | Jun 16, 2021 |
| Date effective | | | | | | Oct 5, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 107 |
| Date of Publication | | | | | | |

| - Caranistan | | | | * | | · |
|---|---------|-------|-------|-------|-------|------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Kazakhstan |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 140 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 85.44 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 54.56 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 55.05 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .15 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 3.96 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .1 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .3 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | .6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 10 |
| Date of Publication | | | | | | |

| Kenya | | 140 | tes. The rest restriction | | | ndicative. Last updated on 2 Sep 2 |
|---|----------------|-------|---------------------------|-------|-------|------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Kenya |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 117.47 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 13.22 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 24.25 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 17.65 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 61.6 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .07 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 28.8 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.07 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.31 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 130 |
| Date approved | | | | | | Jun 28, 2021 |
| Date effective | | | | | | Oct 13, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 13 |
| RDT diagnostic tests (USD mn.) | | | | | | 8.9 |
| PPE (USD mn.) | | | | | | 6.7 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 41.5 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁰⁹ |
| Date of Publication | | | | | | Apr, 2021 |

| | | | | 1 | 0 | ı ı |
|---|---------|-------|-------|-------|-------|---------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Kiribati |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 267.06 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 84.85 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 182.21 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 48.09 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.65 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .09 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 54.7 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.99 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹¹⁰ |
| Date of Publication | | | | | | Jan, 2019 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Korea, Rep |
|---|---------|-------|-------|-------|-------|------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 441.24 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 432.7 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 3.63 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.91 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 86.18 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 84.49 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .85 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 6.87 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .33 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 111 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Kuwait |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 212.06 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 211.25 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | .81 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 78.41 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.16 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.65 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 112 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Kyrgyz Republic |
|---|---------|-------|-------|-------|-------|-----------------|
| | largets | | | | | Kyrgyz Nepublic |
| Vaccines Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 158.08 |
| Bilateral Deals | , 210 | 3.2 | 56.1 | 137.0 | 489.1 | 36.66 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 38.4 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 3.02 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 20.38 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 51.17 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 16.34 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 3.44 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .16 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 20 |
| Date approved | | | | | | Jun 3, 2021 |
| Date effective | | | | | | Sep 22, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .6 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | .4 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 2.6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 113 |
| Date of Publication | | | | | | Jun, 2021 |

| | | | | , | | |
|---|---------|-------|-------|-------|-------|---------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Lao PDR |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 253.52 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 153.52 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 70.34 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 61.57 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 56.44 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 10.62 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .21 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 15 |
| Date approved | | | | | | Jun 9, 2021 |
| Date effective | | | | | | Jul 22, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .7 |
| RDT diagnostic tests (USD mn.) | | | | | | .8 |
| PPE (USD mn.) | | | | | | 1.3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .8 |
| Therapeutics – Others (USD mn.) | | | | | | .3 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹¹⁴ |
| Date of Publication | | | | | | Aug, 2019 |

| | | | | 1 | 0 | 1 1 |
|---|---------|-------|-------|-------|-------|----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Latvia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 643.08 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 10.78 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 69.69 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 54.27 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.7 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 12.38 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.03 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 115 |
| Date of Publication | | | | | | |

| | | | | | | <u> </u> |
|---|---------|-------|-------|-------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Lebanon |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 130.5 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 36.93 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 36.29 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 24.03 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 33.25 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 42.78 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.9 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.63 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .21 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 34 |
| Date approved | | | | | | Jan 20, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 116 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Lesotho |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 172.9 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 9.26 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 12.2 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 71.44 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 38.25 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 52.97 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 32.72 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .17 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.72 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .64 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 25.5 |
| Date approved | | | | | | Jun 1, 2021 |
| Date effective | | | | | | Jun 30, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 117 |
| Date of Publication | | | | | | Jul, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Liberia |
|---|---------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 127.98 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .52 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 7.46 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 44.83 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 44.11 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 1.06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 22.48 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.39 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 8 |
| Date approved | | | | | | Jun 30, 2021 |
| Date effective | | | | | | Aug 3, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .9 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | 3.4 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 4 |
| Therapeutics – Others (USD mn.) | | | | | | 2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | High ¹¹⁸ |
| Date of Publication | | | | | | Dec, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Libya |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 156.42 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 69.84 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 10.51 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 76.06 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 18.17 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 56.79 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .06 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .02 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 119 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Lithuania |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 67.4 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 48.84 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .49 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 21.2 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.3 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 120 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Luxembourg |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 72.41 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 70.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.12 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 37.6 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 15.32 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 123 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Macao SAR, China |
|---|----------------|-------|-------|-------|-------|------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 86.93 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | • |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .18 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | • |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 122 |
| Date of Publication | | | | | | · |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Madagascar |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 101.06 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.06 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 4.84 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 28.3 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 11 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 5.47 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.32 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 100 |
| Date approved | | | | | | Jun 24, 2021 |
| Date effective | | | | | | Jul 26, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.8 |
| RDT diagnostic tests (USD mn.) | | | | | | .5 |
| PPE (USD mn.) | | | | | | 1.8 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 1.7 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 123 |
| Date of Publication | | | | | | Mar, 2021 |

| Ividiawi | | 140 | tes. The reservositivit | y nate and denomic s | ar vemarice targets are r | ndicative. Last updated on 2 Sep 2 |
|---|----------------|-------|-------------------------|----------------------|---------------------------|------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Malawi |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 100.77 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .77 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 10.29 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 57.29 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 17.38 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 6.56 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.37 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 30 |
| Date approved | | | | | | Jun 15, 2021 |
| Date effective | | | | | | Aug 23, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 10.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 6.8 |
| PPE (USD mn.) | | | | | | 5.7 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.6 |
| Therapeutics – Others (USD mn.) | | | | | | 1.2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | High ¹²⁴ |
| Date of Publication | | | | | | Oct, 2020 |

| Malaysia | | | | , | | ı |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Malaysia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 287.72 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 262.69 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 20.79 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.23 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 81.89 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 83.52 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.5 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 5.55 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .52 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 125 |
| Date of Publication | | | | | | |

| THE INTERIOR OF THE INTERIOR O | | | | | | <u> </u> |
|--|---------|-------|-------|-------|-------|---------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Maldives |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 401.57 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 183.95 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 73.58 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 144.04 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 73.8 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 67.19 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 53.5 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 8.29 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .7 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹²⁶ |
| Date of Publication | | | | | | Apr, 2020 |

| IVIAII | | 140 | tes. The lest restrict | y nate and denomic 5 | ar vemance targets are r | ndicative. Last updated on 2 sep 2 |
|---|---------|-------|------------------------|----------------------|--------------------------|------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Mali |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 127.19 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 7.19 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 7.2 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 44.62 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 10.26 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .35 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .24 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 30 |
| Date approved | | | | | | Sep 23, 2021 |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .6 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | 1.6 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1 |
| Therapeutics – Others (USD mn.) | | | | | | .4 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 127 |
| Date of Publication | | | | | | Feb, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Malta |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 89.34 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 95.48 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 6.35 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 23.34 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .78 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 128 |
| Date of Publication | | | | | | |

| | | | | <u> </u> | | <u> </u> |
|---|---------|-------|-------|----------|-------|---------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Marshall Islands |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 152.55 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 52.55 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 39 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 77.5 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | • |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .33 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .15 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹²⁹ |
| Date of Publication | | | | | | May, 2021 |

| Mauritania COMB 40 Ha alab Ta ala | Townsto | | | , | | ndicative. Last updated on 2 Sep |
|---|---------|-------|-------|-------|-------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Mauritania |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 153.9 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 20.09 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 27.96 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 98.44 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 7.41 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 30.85 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 43.44 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 38.6 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .12 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.42 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.65 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 15 |
| Date approved | | | | | | Jun 30, 2021 |
| Date effective | | | | | | Aug 6, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹³⁰ |
| Date of Publication | | | | | | Sep, 2020 |

| | | | | | | <u> </u> |
|---|---------|-------|-------|-------|-------|-----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Mauritius |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 434.11 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 274.85 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 31.8 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 38.33 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 89.13 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 75.27 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 65.7 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.47 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 133 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Mexico |
|---|----------------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 246.8 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 216.33 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 10.12 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 20.35 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 63.1 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 82 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .08 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 48.8 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.05 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 132 |
| Date of Publication | | | | | | |

| interestication is a second se | | | | * | | <u> </u> |
|--|---------|-------|-------|-------|-------|---------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Micronesia, Fed Sts |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 141.93 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 41.93 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 38.81 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 100 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | • |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .22 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹³³ |
| Date of Publication | | | | | | Aug, 2019 |

| | | | | <u>*</u> | | <u> </u> |
|---|---------|-------|-------|----------|-------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Moldova |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 138.29 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 24.87 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 29.69 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 3.73 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 34.74 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 88.59 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 29 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.6 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .11 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 30 |
| Date approved | | | | | | Apr 23, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .3 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .6 |
| Therapeutics – Others (USD mn.) | | | | | | .6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 134 |
| Date of Publication | | | | | | Apr, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Mongolia |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 253.61 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 91.01 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 22.53 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 60.07 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 64.99 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 86.55 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 19.94 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .14 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .12 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 50.7 |
| Date approved | | | | | | Feb 11, 2021 |
| Date effective | | | | | | Jun 8, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | 19 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .7 |
| RDT diagnostic tests (USD mn.) | | | | | | .5 |
| PPE (USD mn.) | | | | | | .3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .5 |
| Therapeutics – Others (USD mn.) | | | | | | .5 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | • |
| Date of Publication | | | | | | |

| Wortenegro | | | | * | | <u>'</u> |
|---|---------|-------|-------|-------|-------|------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Montenegro |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 168.7 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 71.9 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 89.16 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 7.64 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 45.37 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 64.12 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.7 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .3 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 136 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Morocco |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 261.75 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 181.75 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 63.32 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 25.2 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .2 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.07 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .08 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 1.3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 137 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Mozambique |
|---|----------------|-------|-------|-------|-------|----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 215.41 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 34.2 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 7.33 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 53.88 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 39.98 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 69.21 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 42.32 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 9.89 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .57 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 115 |
| Date approved | | | | | | Jun 3, 2021 |
| Date effective | | | | | | Jun 29, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 28.7 |
| RDT diagnostic tests (USD mn.) | | | | | | 4.2 |
| PPE (USD mn.) | | | | | | 5.3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 7.6 |
| Therapeutics – Others (USD mn.) | | | | | | 8.9 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 13 |
| Date of Publication | | | | | | Apr, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Myanmar |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 295.05 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 128.09 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 66.96 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 51.2 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.76 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .42 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 26.76 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .14 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .16 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .02 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 3 |
| RDT diagnostic tests (USD mn.) | | | | | | 6.9 |
| PPE (USD mn.) | | | | | | 27.6 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 5.9 |
| Therapeutics – Others (USD mn.) | | | | | | 2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 139 |
| Date of Publication | | | | | | Jan, 2024 |

| Turning and the state of the st | | | | * | | 1 |
|--|---------|-------|-------|-------|-------|-----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Namibia |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 120.43 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 54.45 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 28.91 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 24.19 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 12.88 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 19.79 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 30.64 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .07 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .08 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 5.79 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.11 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.2 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | 1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 2.7 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 140 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Nauru |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 330.36 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 145.77 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 184.59 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 68.61 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .26 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 143 |
| Date of Publication | | | | | | |

| inepai | | 140 | tes. The lest i ositivit | Y Nate and Genomic 5 | ar vemance targets are r | ndicative. Last updated on 2 Sep 2 |
|---|---------|-------|--------------------------|----------------------|--------------------------|------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Nepal |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 241.91 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 40.44 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 36.2 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 131.76 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 33.51 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 69.51 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 88.05 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .19 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 52.96 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .7 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .33 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 75 |
| Date approved | | | | | | Mar 18, 2021 |
| Date effective | | | | | | Apr 6, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | 165 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 4.4 |
| RDT diagnostic tests (USD mn.) | | | | | | 1.1 |
| PPE (USD mn.) | | | | | | 3 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 3.9 |
| Therapeutics – Others (USD mn.) | | | | | | .3 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 142 |
| Date of Publication | | | | | | May, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Netherlands |
|---|---------|-------|-------|-------|-------|-------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 68.36 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 68.13 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 12.18 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 68.5 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.61 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 143 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | New Caledonia |
|---|----------------|-------|-------|-------|-------|----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 62.72 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .51 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .01 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 144 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | New Zealand |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 722.55 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 720.48 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 2.07 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 80.52 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .55 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .95 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 145 |
| Date of Publication | | | | | | |

| - Tricara Bua | | | | , | | · · · · · · · · · · · · · · · · · · · |
|---|---------|-------|-------|-------|-------|---------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Nicaragua |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 210.16 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 82.35 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 20.14 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 107.67 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 82.8 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 83.11 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .05 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 51.24 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.8 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate 146 |
| Date of Publication | | | | | | Nov, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Niger |
|---|----------------|-------|-------|-------|-------|-------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 132.89 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 3.68 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 9.21 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 11.83 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 70.06 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 14.16 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.47 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 29.2 |
| Date approved | | | | | | Jun 25, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ¹⁴⁷ |
| Date of Publication | | | | | | Oct, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Nigeria |
|---|----------------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 120.96 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 2.13 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 18.83 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 13.58 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 59.68 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 29.56 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .49 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.69 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 400 |
| Date approved | | | | | | Sep 30, 2021 |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 32.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 51.2 |
| PPE (USD mn.) | | | | | | 26.7 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 29 |
| Therapeutics – Others (USD mn.) | | | | | | 15.1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 148 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | North Macedonia |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 208.24 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 81.63 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 32.87 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 26.52 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 67.22 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 39.83 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 83.21 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.34 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 7.43 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .27 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 149 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Norway |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 302.39 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 302.39 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 74.99 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 71.85 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .18 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .09 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 32.2 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 4.86 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 150 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Oman |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 172.53 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 158.56 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 3.83 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 10.14 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 67.35 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .15 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .6 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .26 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 151 |
| Date of Publication | | | | | | • |

| anistan | | | | <u>*</u> | | |
|---|---------|-------|-------|----------|-------|----------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Pakistan |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 143.31 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 49.14 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 4.85 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 9.33 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 56.68 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.71 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 31.38 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .08 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.66 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .25 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | 500 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 152 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Palau |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 271.79 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 237.68 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 34.11 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 94.71 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 100 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | • |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 8.62 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 3.45 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .88 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 153 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Panama |
|---|----------------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 297.8 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 261.81 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 11.48 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 24.51 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 72.11 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 89.48 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.36 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 18.35 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .52 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .2 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 154 |
| Date of Publication | | | | | | |

| - apad rect Camea | | | | * | | · · · · · |
|---|---------|-------|-------|-------|-------|---------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Papua New Guinea |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 102.4 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 2.4 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 2.86 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 50.62 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 10.44 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 9.76 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 30 |
| Date approved | | | | | | Jun 22, 2021 |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 3.4 |
| RDT diagnostic tests (USD mn.) | | | | | | 1 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.2 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁵⁵ |
| Date of Publication | | | | | | Jun, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Paraguay |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 163.71 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 83.11 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 46.84 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 33.76 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 52.29 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.9 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .1 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .27 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .29 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .7 |
| RDT diagnostic tests (USD mn.) | | | | | | .2 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.3 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | • |
| Date of Publication | | | | | | • |

| . 5.4 | | | | * | | 1 1 |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Peru |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 471.65 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 437.79 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 9.1 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 24.77 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 83.33 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .21 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.43 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .71 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .1 |
| RDT diagnostic tests (USD mn.) | | | | | | 1.2 |
| PPE (USD mn.) | | | | | | 2.2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .8 |
| Therapeutics – Others (USD mn.) | | | | | | .8 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 157 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Philippines |
|---|----------------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 289.94 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 169.12 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 29.11 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 11.71 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 63.45 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 66.71 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .13 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 49.16 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .18 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .93 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .56 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 500 |
| Date approved | | | | | | Mar 11, 2021 |
| Date effective | | | | | | Mar 31, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .4 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 18.5 |
| Therapeutics – Others (USD mn.) | | | | | | 3.7 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 158 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Poland |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 58.86 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 53.27 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .08 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .28 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 5.91 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.38 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 159 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Portugal |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 86.58 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 69.99 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 4.88 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 50.63 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .75 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 160 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Qatar |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 301.47 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 278.62 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 22.85 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 102.65 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.59 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.18 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 161 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Romania |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 41.98 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.55 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .26 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .51 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .9 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 162 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Russian Federation |
|---|----------------|-------|-------|-------|-------|---------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 200 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 200 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 52.62 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 91.23 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .13 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.12 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 2.83 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .11 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 163 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Rwanda |
|---|----------------|-------|-------------|-------|-------|-------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 237.89 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 30.13 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 31.2 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 130.7 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 45.87 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 77.91 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 92.66 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .28 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 62.92 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .15 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .77 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .69 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 45 |
| Date approved | | | | | | Apr 16, 2021 |
| Date effective | | | | | | Jun 21, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.7 |
| RDT diagnostic tests (USD mn.) | | | | | | 3.1 |
| PPE (USD mn.) | | | | | | 3.4 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 2.1 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ¹⁶⁴ |
| Date of Publication | | | | | | Jul, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Samoa |
|---|----------------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 276.49 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 95.73 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 29.98 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 150.78 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 90.92 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 68.4 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | 8 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁶⁵ |
| Date of Publication | | | | | | Mar, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | San Marino |
|---|---------|-------|-------|-------|-------|------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 226.02 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 226.02 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 70.03 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 3.32 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 16 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Sao Tome and Principe |
|---|---------|-------|-------|-------|-------|-----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 193.19 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 1.52 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 38.5 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 85.12 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 68.05 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 45.57 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 51.87 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 49.86 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .13 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .91 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .16 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 6.5 |
| Date approved | | | | | | May 13, 2021 |
| Date effective | | | | | | Jun 28, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 167 |
| Date of Publication | | | | | | Feb, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Saudi Arabia |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 210.34 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 205.32 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 5.02 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 70.2 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .17 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 3.47 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .17 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 10 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Senegal |
|---|---------|-------|-------|-------|-------|-------------------------|
| Vaccines | | | | | | Jenegar |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 127.6 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 1.16 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.89 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 44.54 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 6.39 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 36.41 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 17.3 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .04 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 6.44 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 134 |
| Date approved | | | | | | Jun 2, 2021 |
| Date effective | | | | | | Jul 9, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.2 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 2.9 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.1 |
| Therapeutics – Others (USD mn.) | | | | | | .9 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ¹⁶⁹ |
| Date of Publication | | | | | | Jun, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Serbia |
|---|----------------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 136.62 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 121.86 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 5.59 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 9.17 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 47.71 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.74 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 5.94 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .07 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .2 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 1 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Seychelles |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 574.81 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 331.5 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 127.39 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 115.92 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 76.2 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 34.8 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .19 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.52 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.07 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 17 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Sierra Leone |
|---|----------------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 114.49 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 7.49 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 7 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 25.77 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.19 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 16.86 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .11 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .79 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 8.5 |
| Date approved | | | | | | May 28, 2021 |
| Date effective | | | | | | Jun 28, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 6.7 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 4.9 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.3 |
| Therapeutics – Others (USD mn.) | | | | | | .5 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁷² |
| Date of Publication | | | | | | Jul, 2021 |

| <u>emgapore</u> | | | | , | | ' |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Singapore |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 288.67 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 272.76 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 15.91 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 91.74 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 5.16 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 16.27 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.2 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 173 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Slovak Republic |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 669.2 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 668.93 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .27 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 50.73 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 64.37 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .81 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 13.3 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.27 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 17 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Slovenia |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 57.67 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 52.02 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | 2.6 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 12.8 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 6.39 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 175 |
| Date of Publication | | | | | | |

| Solomon Islands | | 110 | tes. The rest restriction | Thate and denomine s | ar vemarioe targets are | indicative. Last updated on 2 Sep |
|---|---------|-------|---------------------------|----------------------|-------------------------|-----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Solomon Islands |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 149.83 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 49.83 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 28.14 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 68.69 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 29.2 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .2 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .8 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ¹⁷⁶ |
| Date of Publication | | | | | | Jun, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Somalia |
|---|----------------|-------|-------------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 131.61 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 1.22 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 10.39 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 14.15 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 38.41 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .26 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 29.28 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .04 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 4.14 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .17 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 45 |
| Date approved | | | | | | Sep 28, 2021 |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.6 |
| RDT diagnostic tests (USD mn.) | | | | | | .9 |
| PPE (USD mn.) | | | | | | .9 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 2.9 |
| Therapeutics – Others (USD mn.) | | | | | | .4 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 177 |
| Date of Publication | | | | | | Nov, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | South Africa |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 117.03 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 101.6 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 15.44 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 32.54 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.99 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .08 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 7.26 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.12 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 1 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | South Sudan |
|---|---------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 121.4 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.4 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 14.55 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 54.3 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .06 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 8.64 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.31 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .96 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | 63.93 |
| Date approved | | | | | | Jun 28, 2021 |
| Date effective | | | | | | Jul 1, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.5 |
| RDT diagnostic tests (USD mn.) | | | | | | .5 |
| PPE (USD mn.) | | | | | | 2.5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .4 |
| Therapeutics – Others (USD mn.) | | | | | | 1.3 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁷⁹ |
| Date of Publication | | | | | | Mar, 2021 |

| - Jan- | | | | <u>*</u> | | · · · · · · · · · · · · · · · · · · · |
|---|---------|-------|-------|----------|-------|---------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Spain |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 85.56 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 57.6 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .46 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 31 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.19 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 180 |
| Date of Publication | | | | | | • |

| | | | | * | <u> </u> | |
|---|---------|-------|-------|-------|--------------|--------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Sri Lanka |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 259.03 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 72.1 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 18.55 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 88.38 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 66.88 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 17.62 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .83 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .53 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | 100 | 80.51 |
| Date approved | | | | | Sep 28, 2021 | Apr 27, 2021 |
| Date effective | | | | | Sep 28, 2021 | May 17, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | 150 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .6 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .7 |
| Therapeutics – Others (USD mn.) | | | | | | .1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 181 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | St Kitts and Nevis |
|---|----------------|-------|-------|-------|-------|---------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 148.4 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 23.28 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 80.3 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 40.34 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 4.48 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 56.6 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .32 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .32 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 1.2 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.14 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 182 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | St Lucia |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 177.52 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 6.2 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 58.92 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 112.4 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 30.48 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 38.4 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 58.22 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .9 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 14.88 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .69 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 183 |
| Date of Publication | | | | | | • |

| Sudan | | | | • | | idicative. Last updated on 2 Sep 2 |
|---|---------|-------|-------|-------|-------|------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Sudan |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 132.88 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 11.88 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 9.94 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 56.86 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .38 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 21.12 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .69 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.2 |
| RDT diagnostic tests (USD mn.) | | | | | | 3 |
| PPE (USD mn.) | | | | | | 5.2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 7.6 |
| Therapeutics – Others (USD mn.) | | | | | | .5 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 185 |
| Date of Publication | | | | | | Sep, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Suriname |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 179.49 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 155.15 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 24.33 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 38.81 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .04 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 49.1 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.39 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 18 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Sweden |
|---|---------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 632.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 632.3 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 73.21 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 74.13 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 4.6 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 11.37 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 8.09 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 187 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Switzerland |
|---|---------|-------|-------|-------|-------|-------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 837.02 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 837.02 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 69.14 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 76.52 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .86 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 40.7 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 3.68 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 1 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Syrian Arab Republic |
|---|----------------|-------|-------|-------|-------|----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 129.85 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 9.85 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 9.44 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 33.72 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 55.68 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .52 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .16 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 189 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Tajikistan |
|---|----------------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 174.22 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 25.79 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 21.54 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 84.32 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 42.57 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 52.52 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .23 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 28.66 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 8.6 |
| Date approved | | | | | | Feb 11, 2021 |
| Date effective | | | | | | Jun 30, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | 25 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.6 |
| RDT diagnostic tests (USD mn.) | | | | | | .5 |
| PPE (USD mn.) | | | | | | .5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .4 |
| Therapeutics – Others (USD mn.) | | | | | | .6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁹⁰ |
| Date of Publication | | | | | | May, 2020 |

| | | | | | | · · · · · · · · · · · · · · · · · · · |
|---|----------------|-------|-------|-------|-------|---------------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Tanzania |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 84.07 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 4.07 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 25.89 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 84.87 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 7.2 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .03 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | No |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 21.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 17.1 |
| PPE (USD mn.) | | | | | | 18.4 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 19.3 |
| Therapeutics – Others (USD mn.) | | | | | | 3.5 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ¹⁹¹ |
| Date of Publication | | | | | | Sep, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Thailand |
|---|---------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 337.77 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 321.65 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 16.12 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 74.55 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.92 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .09 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 31.46 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .62 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.6 |
| RDT diagnostic tests (USD mn.) | | | | | | .7 |
| PPE (USD mn.) | | | | | | 9 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .8 |
| Therapeutics – Others (USD mn.) | | | | | | 2.1 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 192 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Timor-Leste |
|---|----------------|-------|-------|-------|-------|---------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 147.64 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 16.98 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 30.66 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 55.85 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .07 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 25.34 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .11 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.54 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 2.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | .7 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .3 |
| Therapeutics – Others (USD mn.) | | | | | | .4 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 19 |
| Date of Publication | | | | | | Mar, 2019 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Togo |
|---|----------------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 157.41 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 10.23 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 47.18 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 16.49 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 50.93 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 31.92 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .03 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 2.35 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.11 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 29.5 |
| Date approved | | | | | | Jun 10, 2021 |
| Date effective | | | | | | Jun 30, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 4.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 1.1 |
| PPE (USD mn.) | | | | | | 1.5 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .2 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | High ¹⁹⁴ |
| Date of Publication | | | | | | Apr, 2020 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Tonga |
|---|----------------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 212.64 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 49 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 80.46 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 83.18 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 72.26 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .22 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 45.06 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | 5.5 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ¹⁹⁵ |
| Date of Publication | | | | | | Jan, 2025 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Trinidad and Tobago |
|---|---------|-------|-------|-------|-------|----------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 270.93 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 106.89 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 93.88 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 13.17 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 57.01 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 46.96 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 66.15 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .42 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 22.2 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 2.01 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 196 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Tunisia |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 197.77 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 4.19 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 66.82 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 46.77 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 52.04 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 85.44 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .21 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 26.08 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .09 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 9.58 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .11 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 100 |
| Date approved | | | | | | Mar 26, 2021 |
| Date effective | | | | | | May 26, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | .1 |
| RDT diagnostic tests (USD mn.) | | | | | | .8 |
| PPE (USD mn.) | | | | | | .1 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 1.1 |
| Therapeutics – Others (USD mn.) | | | | | | .8 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 197 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Turkey |
|---|---------|-------|-------|-------|-------|-----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 282.21 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 282.21 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 62.69 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.92 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .16 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .77 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .58 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 198 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Turks and Caicos Islands |
|---|----------------|-------|-------|-------|-------|---------------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | • |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 67.14 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .17 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 1.13 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 199 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Tuvalu |
|---|----------------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 221.51 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 62.81 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 58.7 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 49.9 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 46.38 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | • |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 70.44 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | 1.5 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | • |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ²⁰⁰ |
| Date of Publication | | | | | | Jul, 2021 |

| 0841144 | | | | * | | ' |
|---|---------|-------|-------|-------|-------|-------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Uganda |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 138.29 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 13.98 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100.84 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 23.47 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 27.32 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 49.9 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .03 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 52.02 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | On track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .04 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 6.46 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .76 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ²⁰¹ |
| Date of Publication | | | | | | Jun, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Ukraine |
|---|----------------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 305.17 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 170.71 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 8.45 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 46.01 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 34.81 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 62.85 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .09 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 27.38 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .02 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 90 |
| Date approved | | | | | | May 10, 2021 |
| Date effective | | | | | | Aug 1, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 202 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | United Arab Emirates |
|---|---------|-------|-------|-------|-------|-----------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 292.73 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 290.74 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 1.99 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 104.56 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 23.85 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | .49 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .26 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 203 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | United Kingdom |
|---|----------------|-------|-------|-------|-------|-----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 669.34 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 668.55 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | .79 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 75.34 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 78.66 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .02 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.77 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 11.91 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 204 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | United States |
|---|---------|-------|-------|-------|-------|----------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 397.46 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 397.46 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 0 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 0 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 66.5 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 75.6 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 1.37 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 13.9 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 4.21 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 20! |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Uruguay |
|---|----------------|-------|-------|-------|-------|----------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 280.24 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 261.62 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 14.35 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 4.27 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 84.41 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .01 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .57 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .1 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 200 |
| Date of Publication | | | | | | • |

| Uzbekistan | | INO | tes. The Test Positivit | y Nate and Genomic 3 | urveillance targets are n | ndicative. Last updated on 2 Sep |
|---|----------------|-------|-------------------------|----------------------|---------------------------|----------------------------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Uzbekistan |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 206.22 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 124.74 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.48 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 48.13 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .38 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 24.38 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | >1 | .03 | 0.60 | 0.99 | 4.76 | .45 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .04 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Low |
| Risk of Overall Debt Distress | | | | | | Low 207 |
| Date of Publication | | | | | | Apr, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Vanuatu |
|---|----------------|-------|-------|-------|-------|-------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 184.94 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 104.94 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 40.93 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 61.48 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .11 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 42.16 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | • |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .01 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | 3.88 |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | • |
| Therapeutics – Oxygen (USD mn.) | | | | | | • |
| Therapeutics – Others (USD mn.) | | | | | | • |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | Moderate |
| Risk of Overall Debt Distress | | | | | | Moderate ²⁰⁸ |
| Date of Publication | | | | | | Aug, 2021 |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Venezuela, RB |
|---|---------|-------|-------|-------|-------|---------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 167.63 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 101.15 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 1.74 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 64.74 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 50.66 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 80.09 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | • |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .01 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .11 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.9 |
| RDT diagnostic tests (USD mn.) | | | | | | .1 |
| PPE (USD mn.) | | | | | | 5.6 |
| Therapeutics – Oxygen (USD mn.) | | | | | | .3 |
| Therapeutics – Others (USD mn.) | | | | | | 2 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | . 20 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Vietnam |
|---|----------------|-------|-------|-------|-------|-----------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 319.2 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 189.37 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 49.83 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 80 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 85.15 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 90.91 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .42 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 33.06 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Goal met |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .02 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .05 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 0 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 0 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 0 |
| Therapeutics – Others (USD mn.) | | | | | | 0 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | • |
| Risk of Overall Debt Distress | | | | | | |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | West Bank and Gaza |
|---|---------|-------|-------|-------|-------|---------------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 259.3 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 115.36 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 43.94 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 34.56 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 59.5 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 20.08 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 2.91 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | • |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .02 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | • |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | . 211 |
| Date of Publication | | | | | | |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Yemen, Rep |
|---|---------|-------|-------|-------|-------|--------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 120.26 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | .26 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 120 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 0 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 1.37 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 33.93 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | 0 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 6.3 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | 0 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 0 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | 0 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | • |
| World Bank financing for vaccines (USD mn.) | | | | | | 20.0116 |
| Date approved | | | | | | Jun 17, 2021 |
| Date effective | | | | | | Jul 16, 2021 |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | |
| RDT diagnostic tests (USD mn.) | | | | | | |
| PPE (USD mn.) | | | | | | |
| Therapeutics – Oxygen (USD mn.) | | | | | | |
| Therapeutics – Others (USD mn.) | | | | | | |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | |
| Risk of Overall Debt Distress | | | | | | • 212 |
| Date of Publication | | | | | | • |

| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Zambia |
|---|---------|-------|-------|-------|-------|---------------------|
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 137.02 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 0 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 9.25 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 104.52 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 23.26 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 29.32 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 53.82 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .07 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 23.06 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 5.82 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .54 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | 24 |
| Date approved | | | | | | Jun 28, 2021 |
| Date effective | | | | | | |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 12.8 |
| RDT diagnostic tests (USD mn.) | | | | | | 3.7 |
| PPE (USD mn.) | | | | | | 11.8 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 10.4 |
| Therapeutics – Others (USD mn.) | | | | | | 4.6 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | High |
| Risk of Overall Debt Distress | | | | | | High ²¹³ |
| Date of Publication | | | | | | Jul, 2019 |

| | | | | , | | 1 1 |
|---|---------|-------|-------|-------|-------|-----------------|
| COVID-19 Health Tools | Targets | LIC | LMIC | UMIC | HIC | Zimbabwe |
| Vaccines | | | | | | |
| Secured Vaccines (Doses, % of Population) | > 140 | 136.5 | 202.8 | 235.1 | 514.6 | 292.07 |
| Bilateral Deals | | 3.2 | 56.1 | 137.0 | 489.1 | 78 |
| Direct Donations | | 6.9 | 39.4 | 38.1 | 15.5 | 80.94 |
| COVAX | | 115.1 | 90.5 | 37.1 | 8.0 | 100 |
| Other | | 11.3 | 16.8 | 22.9 | 2.1 | 33.13 |
| % of Population Fully Vaccinated as of Today | | 19.0 | 44.4 | 50.5 | 74.5 | 29.54 |
| Percent of Delivered Vaccine Doses that were Administered | | 51.9 | 69.3 | 73.8 | 75.9 | 54.23 |
| Current Rate of Daily Vaccination (per 100 people) | | .11 | .09 | .06 | .06 | .04 |
| COVAX AMC Allocation (Course, per 100 people) | | 22.8 | 27.4 | 7.3 | 0 | 16.98 |
| Progress Towards 70% Full Vaccine Coverage | | | | | | Off track |
| Diagnostics | | | | | | |
| Daily Testing Rate (per 1000 people) | > 1 | .03 | 0.60 | 0.99 | 4.76 | .05 |
| Test Positivity Rate (%, 7-day average) | < 5 | 4.16 | 6.05 | 14.14 | 20.43 | 4.21 |
| Genomic Surveillance (Sequences Shared, % of Cases) | > 1-5 | 1.34 | 1.20 | 0.55 | 2.83 | .36 |
| Financing for Vaccines, Diagnostics, Treatments, PPE | | | | | | |
| AVAT orders placed | | | | | | Yes |
| World Bank financing for vaccines (USD mn.) | | | | | | • |
| Date approved | | | | | | • |
| Date effective | | | | | | • |
| ADB financing for vaccines (USD mn.) | | | | | | • |
| Global Fund COVID-19 Response Mechanism | | | | | | |
| PCR diagnostic tests (USD mn.) | | | | | | 1.1 |
| RDT diagnostic tests (USD mn.) | | | | | | 0 |
| PPE (USD mn.) | | | | | | 30.2 |
| Therapeutics – Oxygen (USD mn.) | | | | | | 5.4 |
| Therapeutics – Others (USD mn.) | | | | | | .4 |
| IMF-WB Joint Debt Sustainability Analysis | | | | | | |
| Risk of External Debt Distress | | | | | | In distress |
| Risk of Overall Debt Distress | | | | | | In distress 214 |
| Date of Publication | | | | | | Feb, 2020 |